Predictive Efficacy of the Advanced Lung Cancer Inflammation Index in Hepatocellular Carcinoma After Hepatectomy
Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients wit...
Saved in:
Published in | Journal of inflammation research Vol. 17; pp. 5197 - 5210 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2024
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
ISSN | 1178-7031 1178-7031 |
DOI | 10.2147/JIR.S468215 |
Cover
Loading…
Abstract | Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients with HCC.
A cohort comprising 1654 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital from 2013 to 2019 was enrolled. Patients were stratified into two groups according to the median ALI level, and then subjected to propensity score matching (PSM) in a 1:1 ratio. Kaplan-Meier survival curves, the traditional Cox proportional hazards (CPH) model, and machine learning (ML) models were employed to analyze and evaluate ALI's prognostic significance. Furthermore, ALI's prognostic value in digestive system tumors was validated via analysis of the National Health and Nutrition Examination Survey (NHANES) database.
After applying PSM, a final cohort of 1284 patients, categorized into high and low ALI groups, revealed a significantly reduced survival time in the low ALI cohort. Univariate and multivariate Cox analyses identified ALI, BCLC stage, CK19, Hepatitis B virus (HBV) DNA, lymph node metastasis, and microvascular invasion (MVI) as independent predictors of prognosis. Both traditional CPH and ML models incorporating ALI demonstrated excellent predictive accuracy, validated through calibration curves, time-dependent ROC curves, and decision curve analysis. Furthermore, the prognostic value of ALI in digestive tumors was confirmed in the NHANES database.
The ALI exhibits potential as a prognostic predictor in patients with HCC following hepatectomy, providing valuable insights into postoperative survival. |
---|---|
AbstractList | Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients with HCC.
A cohort comprising 1654 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital from 2013 to 2019 was enrolled. Patients were stratified into two groups according to the median ALI level, and then subjected to propensity score matching (PSM) in a 1:1 ratio. Kaplan-Meier survival curves, the traditional Cox proportional hazards (CPH) model, and machine learning (ML) models were employed to analyze and evaluate ALI's prognostic significance. Furthermore, ALI's prognostic value in digestive system tumors was validated via analysis of the National Health and Nutrition Examination Survey (NHANES) database.
After applying PSM, a final cohort of 1284 patients, categorized into high and low ALI groups, revealed a significantly reduced survival time in the low ALI cohort. Univariate and multivariate Cox analyses identified ALI, BCLC stage, CK19, Hepatitis B virus (HBV) DNA, lymph node metastasis, and microvascular invasion (MVI) as independent predictors of prognosis. Both traditional CPH and ML models incorporating ALI demonstrated excellent predictive accuracy, validated through calibration curves, time-dependent ROC curves, and decision curve analysis. Furthermore, the prognostic value of ALI in digestive tumors was confirmed in the NHANES database.
The ALI exhibits potential as a prognostic predictor in patients with HCC following hepatectomy, providing valuable insights into postoperative survival. Background: Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients with HCC. Methods: A cohort comprising 1654 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital from 2013 to 2019 was enrolled. Patients were stratified into two groups according to the median ALI level, and then subjected to propensity score matching (PSM) in a 1:1 ratio. Kaplan-Meier survival curves, the traditional Cox proportional hazards (CPH) model, and machine learning (ML) models were employed to analyze and evaluate ALI's prognostic significance. Furthermore, ALI's prognostic value in digestive system tumors was validated via analysis of the National Health and Nutrition Examination Survey (NHANES) database. Results: After applying PSM, a final cohort of 1284 patients, categorized into high and low ALI groups, revealed a significantly reduced survival time in the low ALI cohort. Univariate and multivariate Cox analyses identified ALI, BCLC stage, CK19, Hepatitis B virus (HBV) DNA, lymph node metastasis, and microvascular invasion (MVI) as independent predictors of prognosis. Both traditional CPH and ML models incorporating ALI demonstrated excellent predictive accuracy, validated through calibration curves, time-dependent ROC curves, and decision curve analysis. Furthermore, the prognostic value of ALI in digestive tumors was confirmed in the NHANES database. Conclusion: The ALI exhibits potential as a prognostic predictor in patients with HCC following hepatectomy, providing valuable insights into postoperative survival. Keywords: advanced lung cancer inflammatory index, ALI, hepatocellular carcinoma, HCC, prognosis, Cox regression, machine learning, ML Xin Qiu,1,2,* Shuang Shen,1,* Donghong Lu,2 Nizhen Jiang,3 Yifei Feng,3 Jindu Li,1 Chenglei Yang,1 Bangde Xiang1,4,5 1Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China; 2Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; 3Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China; 4Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, People’s Republic of China; 5Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Nanning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Bangde Xiang; Chenglei Yang, Email xiangbangde@gxmu.edu.cn; chenglei2017yang@163.comBackground: Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients with HCC.Methods: A cohort comprising 1654 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital from 2013 to 2019 was enrolled. Patients were stratified into two groups according to the median ALI level, and then subjected to propensity score matching (PSM) in a 1:1 ratio. Kaplan-Meier survival curves, the traditional Cox proportional hazards (CPH) model, and machine learning (ML) models were employed to analyze and evaluate ALI’s prognostic significance. Furthermore, ALI’s prognostic value in digestive system tumors was validated via analysis of the National Health and Nutrition Examination Survey (NHANES) database.Results: After applying PSM, a final cohort of 1284 patients, categorized into high and low ALI groups, revealed a significantly reduced survival time in the low ALI cohort. Univariate and multivariate Cox analyses identified ALI, BCLC stage, CK19, Hepatitis B virus (HBV) DNA, lymph node metastasis, and microvascular invasion (MVI) as independent predictors of prognosis. Both traditional CPH and ML models incorporating ALI demonstrated excellent predictive accuracy, validated through calibration curves, time-dependent ROC curves, and decision curve analysis. Furthermore, the prognostic value of ALI in digestive tumors was confirmed in the NHANES database.Conclusion: The ALI exhibits potential as a prognostic predictor in patients with HCC following hepatectomy, providing valuable insights into postoperative survival.Keywords: advanced lung cancer inflammatory index, ALI, hepatocellular carcinoma, HCC, prognosis, Cox regression, machine learning, ML Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients with HCC.BackgroundHepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study examines the predictive efficacy of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the post-hepatectomy prognosis of patients with HCC.A cohort comprising 1654 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital from 2013 to 2019 was enrolled. Patients were stratified into two groups according to the median ALI level, and then subjected to propensity score matching (PSM) in a 1:1 ratio. Kaplan-Meier survival curves, the traditional Cox proportional hazards (CPH) model, and machine learning (ML) models were employed to analyze and evaluate ALI's prognostic significance. Furthermore, ALI's prognostic value in digestive system tumors was validated via analysis of the National Health and Nutrition Examination Survey (NHANES) database.MethodsA cohort comprising 1654 HCC patients who underwent hepatectomy at Guangxi Medical University Cancer Hospital from 2013 to 2019 was enrolled. Patients were stratified into two groups according to the median ALI level, and then subjected to propensity score matching (PSM) in a 1:1 ratio. Kaplan-Meier survival curves, the traditional Cox proportional hazards (CPH) model, and machine learning (ML) models were employed to analyze and evaluate ALI's prognostic significance. Furthermore, ALI's prognostic value in digestive system tumors was validated via analysis of the National Health and Nutrition Examination Survey (NHANES) database.After applying PSM, a final cohort of 1284 patients, categorized into high and low ALI groups, revealed a significantly reduced survival time in the low ALI cohort. Univariate and multivariate Cox analyses identified ALI, BCLC stage, CK19, Hepatitis B virus (HBV) DNA, lymph node metastasis, and microvascular invasion (MVI) as independent predictors of prognosis. Both traditional CPH and ML models incorporating ALI demonstrated excellent predictive accuracy, validated through calibration curves, time-dependent ROC curves, and decision curve analysis. Furthermore, the prognostic value of ALI in digestive tumors was confirmed in the NHANES database.ResultsAfter applying PSM, a final cohort of 1284 patients, categorized into high and low ALI groups, revealed a significantly reduced survival time in the low ALI cohort. Univariate and multivariate Cox analyses identified ALI, BCLC stage, CK19, Hepatitis B virus (HBV) DNA, lymph node metastasis, and microvascular invasion (MVI) as independent predictors of prognosis. Both traditional CPH and ML models incorporating ALI demonstrated excellent predictive accuracy, validated through calibration curves, time-dependent ROC curves, and decision curve analysis. Furthermore, the prognostic value of ALI in digestive tumors was confirmed in the NHANES database.The ALI exhibits potential as a prognostic predictor in patients with HCC following hepatectomy, providing valuable insights into postoperative survival.ConclusionThe ALI exhibits potential as a prognostic predictor in patients with HCC following hepatectomy, providing valuable insights into postoperative survival. |
Audience | Academic |
Author | Jiang, Nizhen Li, Jindu Lu, Donghong Feng, Yifei Yang, Chenglei Qiu, Xin Shen, Shuang Xiang, Bangde |
Author_xml | – sequence: 1 givenname: Xin surname: Qiu fullname: Qiu, Xin – sequence: 2 givenname: Shuang orcidid: 0000-0002-0845-2533 surname: Shen fullname: Shen, Shuang – sequence: 3 givenname: Donghong surname: Lu fullname: Lu, Donghong – sequence: 4 givenname: Nizhen orcidid: 0009-0006-1752-0397 surname: Jiang fullname: Jiang, Nizhen – sequence: 5 givenname: Yifei surname: Feng fullname: Feng, Yifei – sequence: 6 givenname: Jindu surname: Li fullname: Li, Jindu – sequence: 7 givenname: Chenglei surname: Yang fullname: Yang, Chenglei – sequence: 8 givenname: Bangde surname: Xiang fullname: Xiang, Bangde |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39104905$$D View this record in MEDLINE/PubMed |
BookMark | eNptkluLEzEAhYOsuGvdJ99lQBBBWpNJZpI8SSmrWykoXp5DJpc2y0zSzWQW--_NtHVpZZOH3L5zcjsvwYUP3gDwGsFZiQj9-HX5Y_aT1KxE1TNwhRBlUwoxujjpX4Lrvr-DY6GQlOQFuMQcQcJhdQW236PRTiX3YIoba52SalcEW6SNKeb6QXpldLEa_LpYjP1YLL1tZdfJ5ILPA23-FM4Xt2YrU1CmbYdWxsxG5XzoZDG3KYv2y0al0O1egedWtr25PrYT8Pvzza_F7XT17ctyMV9NVUXqNGUVxwgiQiBjuG5YpXRV04byqiEQakkwNdRgi2rTcCMR08rY2tYV01TWtsQTsDz46iDvxDa6TsadCNKJ_USIayFjcqo1IqtxpSzjtGGEE8pZwxRhqsJIE5y3moBPB6_t0HQm7-RTlO2Z6fmKdxuxDg8CoZLzmrDs8P7oEMP9YPokOtePzyW9CUMvMGS8QpiiOqNvD-ha5rM5b0O2VCMu5gzykpU1HanZE1Su2nRO5YxYl-fPBO9OBBsj27TpQzuM_9ifg29OL_t4y3-ZycCHA6Bi6Pto7COCoBhDKXIoxTGUmUb_0cqlfXrygV37pOYvb6Dhmg |
CitedBy_id | crossref_primary_10_1186_s12876_025_03762_w |
Cites_doi | 10.1016/j.ijbiomac.2023.129070 10.1111/1759-7714.14646 10.21037/hbsn-23-631 10.5582/bst.2023.01212 10.3389/fonc.2023.1021672 10.1007/s11547-023-01753-z 10.21037/jgo-23-315 10.3945/an.115.009258 10.1038/s41571-023-00848-w 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E 10.1002/jcsm.13358 10.3390/ijms242417626 10.1002/tox.24121 10.1111/liv.12818 10.1097/HEP.0000000000000466 10.1055/s-2007-1007122 10.1016/j.clnu.2024.05.039 10.1200/JCO.2002.20.6.1527 10.7150/ijms.88039 10.1096/fj.202001615RRR 10.3322/caac.21763 10.3390/biom13121803 10.1159/000530495 10.1093/bib/bbad487 10.1016/j.ccell.2020.04.005 10.1007/s10147-023-02410-1 10.3389/fonc.2022.936206 10.21873/anticanres.16714 10.1021/acsbiomaterials.3c01744 10.3389/pore.2022.1610315 10.1097/HEP.0000000000000237 10.1159/000531324 10.3389/fonc.2023.997314 10.1016/j.compbiomed.2024.108260 10.3389/fgene.2022.1047326 10.3389/fimmu.2022.808101 10.3389/fonc.2024.1294253 10.1016/j.cell.2011.02.013 10.1200/JCO.2014.57.9151 10.1093/annonc/mdy093 10.1038/s41416-022-01826-2 10.1186/s12885-022-10477-8 10.3892/ol.2023.14024 10.3390/cancers12071986 |
ContentType | Journal Article |
Copyright | 2024 Qiu et al. COPYRIGHT 2024 Dove Medical Press Limited 2024 Qiu et al. 2024 Qiu et al. |
Copyright_xml | – notice: 2024 Qiu et al. – notice: COPYRIGHT 2024 Dove Medical Press Limited – notice: 2024 Qiu et al. 2024 Qiu et al. |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.2147/JIR.S468215 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Qiu et al |
EISSN | 1178-7031 |
EndPage | 5210 |
ExternalDocumentID | oai_doaj_org_article_a1835cf897b8494798b8c48c531d43a4 PMC11299648 A809282676 39104905 10_2147_JIR_S468215 |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 0YH 29K 2WC 53G 5VS 7RV 8FE 8FH 8FI 8FJ 8G5 AAYXX ABUWG ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BKEYQ BPHCQ BVXVI CCPQU CITATION D-I DIK DWQXO E3Z EBD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HYE IAO IHR IHW IPNFZ ITC KQ8 LK8 M2O M48 M7P M~E NAPCQ OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 UKHRP VDV NPM PPXIY PQGLB PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c546t-85931014408836b85cd567b795b400da437e7e3f16eb9ea18dcef6f658d7a6f23 |
IEDL.DBID | M48 |
ISSN | 1178-7031 |
IngestDate | Wed Aug 27 01:25:23 EDT 2025 Thu Aug 21 18:31:59 EDT 2025 Fri Jul 11 08:55:14 EDT 2025 Tue Jun 17 22:04:16 EDT 2025 Tue Jun 10 21:04:18 EDT 2025 Thu May 22 21:23:22 EDT 2025 Mon Jul 21 06:05:18 EDT 2025 Tue Jul 01 03:14:00 EDT 2025 Thu Apr 24 23:06:05 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | advanced lung cancer inflammatory index HCC Cox regression machine learning prognosis ALI hepatocellular carcinoma ML |
Language | English |
License | https://creativecommons.org/licenses/by-nc/3.0 2024 Qiu et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c546t-85931014408836b85cd567b795b400da437e7e3f16eb9ea18dcef6f658d7a6f23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
ORCID | 0000-0002-0845-2533 0009-0006-1752-0397 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/JIR.S468215 |
PMID | 39104905 |
PQID | 3089513716 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a1835cf897b8494798b8c48c531d43a4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11299648 proquest_miscellaneous_3089513716 gale_infotracmisc_A809282676 gale_infotracacademiconefile_A809282676 gale_healthsolutions_A809282676 pubmed_primary_39104905 crossref_primary_10_2147_JIR_S468215 crossref_citationtrail_10_2147_JIR_S468215 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-01-01 |
PublicationDateYYYYMMDD | 2024-01-01 |
PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | Journal of inflammation research |
PublicationTitleAlternate | J Inflamm Res |
PublicationYear | 2024 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | Zhou (ref22) 2023; 12 Singal (ref1) 2023; 78 Xie (ref9) 2024; 43 Ruan (ref11) 2023; 14 Jia (ref34) 2023; 24 Duran-Güell (ref39) 2021; 35 Wen (ref17) 2024; 14 ref19 Nindra (ref43) 2022; 13 Johnson (ref23) 2015; 33 Zhang (ref38) 2023; 258 Wang (ref44) 2022; 12 Sonehara (ref12) 2023; 101 Vauthey (ref25) 2002; 20 Zhang (ref29) 2022; 13 Wang (ref33) 2024; 21 Polk (ref45) 2022; 28 Park (ref4) 2015; 35 Liu (ref18) 2023; 26 Llovet (ref21) 1999; 19 Okuda (ref24) 1985; 56 Wu (ref37) 2024; 10 Klobuch (ref42) 2024; 21 Hanahan (ref7) 2011; 144 Almasaudi (ref40) 2020; 12 Shi (ref6) 2024; 172 Liu (ref31) 2023; 25 Huo (ref15) 2023; 14 Cheng (ref16) 2022; 13 Arends (ref26) 2018; 29 Qu (ref30) 2024; 39 Siegel (ref2) 2023; 73 Ladd (ref3) 2023; 79 Li (ref5) 2023; 13 Hu (ref28) 2023; 17 McGovern (ref35) 2022; 127 Tajan (ref36) 2020; 37 Ahluwalia (ref20) 2016; 7 Yang (ref32) 2024 Gavriilidis (ref8) 2024; 13 Zhang (ref14) 2023; 28 Pang (ref27) 2023; 13 Asaka (ref10) 2023; 43 Huang (ref13) 2022; 22 Mosca (ref41) 2023; 13 |
References_xml | – volume: 258 start-page: 129070 year: 2023 ident: ref38 publication-title: Int J Biol Macromol doi: 10.1016/j.ijbiomac.2023.129070 – volume: 13 start-page: 3058 year: 2022 ident: ref43 publication-title: Thoracic Cancer doi: 10.1111/1759-7714.14646 – volume: 13 start-page: 509 year: 2024 ident: ref8 publication-title: Hepatobiliary Surg Nutr doi: 10.21037/hbsn-23-631 – volume: 17 start-page: 369 year: 2023 ident: ref28 publication-title: Biosci Trends doi: 10.5582/bst.2023.01212 – volume: 13 start-page: 1021672 year: 2023 ident: ref27 publication-title: Front Oncol doi: 10.3389/fonc.2023.1021672 – year: 2024 ident: ref32 publication-title: La Radiol Med doi: 10.1007/s11547-023-01753-z – volume: 14 start-page: 1653 year: 2023 ident: ref15 publication-title: J Gastrointest Oncol doi: 10.21037/jgo-23-315 – volume: 7 start-page: 121 year: 2016 ident: ref20 publication-title: Adv Nutr doi: 10.3945/an.115.009258 – volume: 21 start-page: 173 year: 2024 ident: ref42 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-023-00848-w – volume: 56 start-page: 918 year: 1985 ident: ref24 publication-title: Cancer doi: 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E – volume: 14 start-page: 2813 year: 2023 ident: ref11 publication-title: J Cachexia Sarcopenia Muscle doi: 10.1002/jcsm.13358 – volume: 24 start-page: 17626 year: 2023 ident: ref34 publication-title: Int J Mol Sci doi: 10.3390/ijms242417626 – volume: 39 start-page: 2512 year: 2024 ident: ref30 publication-title: Environ Toxicol doi: 10.1002/tox.24121 – volume: 35 start-page: 2155 year: 2015 ident: ref4 publication-title: Liver Int doi: 10.1111/liv.12818 – volume: 78 start-page: 1922 year: 2023 ident: ref1 publication-title: Hepatology doi: 10.1097/HEP.0000000000000466 – ident: ref19 – volume: 19 start-page: 329 year: 1999 ident: ref21 publication-title: Semin Liver Disease doi: 10.1055/s-2007-1007122 – volume: 43 start-page: 1791 year: 2024 ident: ref9 publication-title: Clin Nutr doi: 10.1016/j.clnu.2024.05.039 – volume: 20 start-page: 1527 year: 2002 ident: ref25 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.6.1527 – volume: 21 start-page: 207 year: 2024 ident: ref33 publication-title: Int J Med Sci doi: 10.7150/ijms.88039 – volume: 35 start-page: e21365 year: 2021 ident: ref39 publication-title: FASEB J doi: 10.1096/fj.202001615RRR – volume: 73 start-page: 17 year: 2023 ident: ref2 publication-title: CA doi: 10.3322/caac.21763 – volume: 13 start-page: 1803 year: 2023 ident: ref41 publication-title: Biomolecules doi: 10.3390/biom13121803 – volume: 12 start-page: 405 year: 2023 ident: ref22 publication-title: Liver Cancer doi: 10.1159/000530495 – volume: 25 year: 2023 ident: ref31 publication-title: Briefings Bioinf doi: 10.1093/bib/bbad487 – volume: 37 start-page: 767 year: 2020 ident: ref36 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.04.005 – volume: 28 start-page: 1616 year: 2023 ident: ref14 publication-title: Int J Clin Oncol doi: 10.1007/s10147-023-02410-1 – volume: 12 start-page: 936206 year: 2022 ident: ref44 publication-title: Front Oncol doi: 10.3389/fonc.2022.936206 – volume: 43 start-page: 5139 year: 2023 ident: ref10 publication-title: Anticancer Res doi: 10.21873/anticanres.16714 – volume: 10 start-page: 743 year: 2024 ident: ref37 publication-title: ACS Biomater Sci Eng doi: 10.1021/acsbiomaterials.3c01744 – volume: 28 start-page: 1610315 year: 2022 ident: ref45 publication-title: Pathol Oncol Res doi: 10.3389/pore.2022.1610315 – volume: 79 start-page: 926 year: 2023 ident: ref3 publication-title: Hepatology doi: 10.1097/HEP.0000000000000237 – volume: 101 start-page: 425 year: 2023 ident: ref12 publication-title: Oncology doi: 10.1159/000531324 – volume: 13 start-page: 997314 year: 2023 ident: ref5 publication-title: Front Oncol doi: 10.3389/fonc.2023.997314 – volume: 172 start-page: 108260 year: 2024 ident: ref6 publication-title: Comput Biol Med doi: 10.1016/j.compbiomed.2024.108260 – volume: 13 start-page: 1047326 year: 2022 ident: ref16 publication-title: Front Genetics doi: 10.3389/fgene.2022.1047326 – volume: 13 start-page: 808101 year: 2022 ident: ref29 publication-title: Front Immunol doi: 10.3389/fimmu.2022.808101 – volume: 14 start-page: 1294253 year: 2024 ident: ref17 publication-title: Front Oncol doi: 10.3389/fonc.2024.1294253 – volume: 144 start-page: 646 year: 2011 ident: ref7 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 33 start-page: 550 year: 2015 ident: ref23 publication-title: J clin oncol doi: 10.1200/JCO.2014.57.9151 – volume: 29 start-page: ii27 year: 2018 ident: ref26 publication-title: Ann Oncol doi: 10.1093/annonc/mdy093 – volume: 127 start-page: 379 year: 2022 ident: ref35 publication-title: Br J Cancer doi: 10.1038/s41416-022-01826-2 – volume: 22 start-page: 1370 year: 2022 ident: ref13 publication-title: BMC Cancer doi: 10.1186/s12885-022-10477-8 – volume: 26 start-page: 437 year: 2023 ident: ref18 publication-title: Oncol Lett doi: 10.3892/ol.2023.14024 – volume: 12 start-page: 1986 year: 2020 ident: ref40 publication-title: Cancers doi: 10.3390/cancers12071986 |
SSID | ssj0000070424 |
Score | 2.3289356 |
Snippet | Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery. This study... Background: Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its poor prognosis and high recurrence rates post-surgery.... Xin Qiu,1,2,* Shuang Shen,1,* Donghong Lu,2 Nizhen Jiang,3 Yifei Feng,3 Jindu Li,1 Chenglei Yang,1 Bangde Xiang1,4,5 1Department of Hepatobiliary Surgery,... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 5197 |
SubjectTerms | advanced lung cancer inflammatory index ali Cancer cox regression Development and progression Gastrointestinal diseases hcc Health surveys hepatocellular carcinoma Hepatoma Inflammation Lung cancer Machine learning Medical colleges Metastasis Oncology, Experimental Original Research Prognosis World health |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bSxtBFB6KD6UvorXVrdaOIBQKq0lmdmb2MUokShXRBnwb5rYYaHZDjKD_vufsrGGXCr74tps5hD23mW9u3yHkEJCQ6VtrUm-cSHnf9lIlXJZaG_oquMB9vZhzeSXGE35xl921Sn3hmbBIDxwNd2wg5jJXqFxaxXMuc2WV48pB7HjOTM0ECmNeazIVga_EPb14IQ9L8RxfnN8c3XKhBlgAtzUE1Uz9__fHrQGpe1iyNfqcbZD1BjbSYfzcTfIhlJ_Jx8tmY3yLzK8X-Ix9Fx0hK4Rxz7QqKMA7Omy2-elvSGx6is8Lel4WEAvx3iK8-PBEpyUdw-C0rHAxH0-nguwC_r6aGTrEUuKxGZf5Z89fyORs9Od0nDbFFFKXcbFMkdcM6_Jy6FaYsCpzPhPSyjyzkMbecCaDDKzoi2DzAFYHhQtRAEDx0ohiwL6StbIqww6hwgcwecbZgBU8MG8AIxjFDWMCN1pdQn692Fe7hmkcC1781TDjQGdocIZunJGQw5XwPBJsvC52go5aiSArdv0DxIpuYkW_FSsJ-YFu1vGK6Sq39VD1cph6CikS8rOWwOyGTwZnxUsKoDjyZHUk9zqSkJWu03zwEkoam_AoWxmqxwfNegpQLYN5akK2Y2ittGIA3njeA21VJ-g6andbyul9TQqOuDkXXH17D0Ptkk8DAG9xqWmPrC0Xj-E7gK-l3a_z7B-cuytz priority: 102 providerName: Directory of Open Access Journals |
Title | Predictive Efficacy of the Advanced Lung Cancer Inflammation Index in Hepatocellular Carcinoma After Hepatectomy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39104905 https://www.proquest.com/docview/3089513716 https://pubmed.ncbi.nlm.nih.gov/PMC11299648 https://doaj.org/article/a1835cf897b8494798b8c48c531d43a4 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1ba9swFBalhdKXse7qrcs0KAwG7uJIluSHMdKSLi1LKd0CeROSLG-F1u7cFJp_33MsJ8Rb9xKc6MRYPrdP0rkQsg9IyCTWmjg3TsQ8sf1YCZfG1vpEeed53mzmTM7EeMpPZ-lsgyybcbYv8PbRpR32k5rWVwf3fxZfQeG_YBhzwuXn05OLgx9cqAEmm2-BS5LYw2HS4vyAgyUe8YVGKyrGmu0hV-_v_--QbQYOlGfYzm7NUTX1_P-12mtuqxtSueajjp-SJy24pMMgDbtkw5fPyPakPT5_Tm7Oa7xGC0dHWDvCuAWtCgogkA7bYAD6HdSfHuF1TU_KAiQmZDfCl9zf08uSjsGFzSvc8scYVqCt4fbVtaFDbDgehvEw4HrxgkyPRz-PxnHbciF2KRfzGKufYfdeDsaHCatSl6dCWpmlFpQ9N5xJLz0rEuFt5k2iYMKFKADG5NKIYsBeks2yKv1rQkXuB4DfOBuwgnuWG0ASRnHDmMDjWBeRT8v3q11bjxzbYlxpWJcgXzTwRbd8icj-ivgmlOF4nOwQGbUiwdrZzQ9V_Uu3qqjhqVnqCpVJq3jGZaasclw5sEY5Z4ZH5D2yWYdE1JUF0EPVz2CBKqSIyMeGAqUSHhmYFVIZYOJYTatDudehBN11neEPS1HSOIQBb6Wv7m416yvAvgxWsxF5FURrNaulhEZEdYSuM-3uSHn5uykdjug6E1y9-e9N35KdAeC2sMu0Rzbn9Z1_B7hrbntk63B0dn7Ra_Yt4PPbLOk1evYAhOsq6w |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+Efficacy+of+the+Advanced+Lung+Cancer+Inflammation+Index+in+Hepatocellular+Carcinoma+After+Hepatectomy&rft.jtitle=Journal+of+inflammation+research&rft.au=Qiu%2C+Xin&rft.au=Shen%2C+Shuang&rft.au=Lu%2C+Donghong&rft.au=Jiang%2C+Nizhen&rft.date=2024-01-01&rft.issn=1178-7031&rft.eissn=1178-7031&rft.volume=17&rft.spage=5197&rft_id=info:doi/10.2147%2FJIR.S468215&rft_id=info%3Apmid%2F39104905&rft.externalDocID=39104905 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7031&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7031&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7031&client=summon |